FIELD: biotechnology.
SUBSTANCE: described are an antibody against the programmed death ligand (PD-L1) and an application thereof for producing a medicinal product for treating a neoplastic disease, an isolated nucleic acid molecule, a pharmaceutical composition, an expression vector, a host cell for expression of the antibody or an antigen-binding fragment thereof, and a method for obtaining the antibody.
EFFECT: invention provides a possibility of obtaining a new antibody against the programmed death ligand and effectively using said antibody in treatment or prevention of conditions associated with PD-L1, in particular, such as a PD-L1-positive tumour.
21 cl, 8 dwg, 2 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND ANTIBODIES FOR IMMUNE RESPONSE MODULATION | 2016 |
|
RU2757489C2 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO GD2 (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2796937C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2013 |
|
RU2599417C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2016 |
|
RU2732924C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2006 |
|
RU2494107C2 |
